It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

Scientists at the University of Michigan Rogel Cancer Center have found a promising new way to fight one of the most ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

Prostate cancer remains one of the most significant health concerns for men worldwide, with detection and treatment options ...

The Nuclear Medicine Department at Ridley-Tree Cancer Center (now part of Sutter Health) has announced greater capabilities to treat prostate cancer using ...

Sophia Kamran, MD, discusses how salvage therapy after biochemical recurrence may improve outcomes for patients with prostate ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

A group of senior gym-goers who got their prostates checked at roughly the same time were shocked to find almost half of them ...

Comedian Milton Jones has cancelled summer tour dates after revealing he's been diagnosed with prostate cancer.